Specific gastric cancer population key to positive final NICE guidance on Roche's Herceptin
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, has today published final guidance recommending Roche's anticancer Herceptin (trastuzumab) for some patients with metastatic gastric cancer. Defining a specific patient subgroup – patients who express high levels of HER2 – proved the key to winning a positive recommendation.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.